Research Archive — Cannabinoid Monographs
Cannabinoid Monographs
Each monograph is a comprehensive research reference for a single cannabinoid — compound identity, pharmacological profile, evidence by domain, and open research questions. They are written for readers who want the complete picture of one compound rather than its role in a specific health topic. The evidence tiers documented here govern how each compound is presented throughout the archive.
CBG — Cannabigerol
The founding research compound of this archive — the most developed evidence base of the four monographs, including the first controlled human trial.
Primary · Founding compound
CBD — Cannabidiol
The broadest human evidence base of any cannabinoid in common use — mechanisms, evidence tiers, and an honest accounting of what is and is not established.
Full standing throughout archive
CBN — Cannabinol
A THC degradation product whose sleep reputation substantially exceeds its controlled evidence base — what the pharmacology shows and what the research has actually found.
Tier 2 · Sleep claim addressed directly
CBC — Cannabichromene
A non-psychoactive cannabinoid with a pharmacological profile centered on TRPA1 channels rather than cannabinoid receptors — the least researched of the four.
Tier 2 · Shorter monograph reflects evidence depth